Climedo receives five million euros in seed financing

Pharmaceutical companies, clinics and health authorities use Climedo's software to record symptoms in their study participants or patients.

Climedo has completed a seed financing round of five million euros. In addition to the leading investor Nauta Capital, Westtech Ventures and business angels such as Christian Wallwiener from WMC Healthcare also participated.

Climedo intends to use the capital from the financing round to expand within Europe and further develop its software. The start-up's platform enables the electronic collection of data for clinical trials in compliance with data protection regulations. Study participants keep an electronic patient diary in which they enter their symptoms. Climedo enables companies to conduct clinical trials more efficiently and cost-effectively. In future, all communication between study coordinators, doctors and patients should be possible via the platform. The start-up is also planning to integrate interfaces for telemedicine and wearables.

Sascha Ritz, Dragan Mileski and Veronika Schweighart founded the company in Munich in 2017. The start-up currently employs around 50 people. "We have set ourselves the ambitious goal of becoming the market leader in Europe for patient-centered, electronic data collection by 2024," says Climedo co-founder and Managing Director Sascha Ritz. The start-up is already working with clinics such as Berlin's Charité hospital and pharmaceutical companies. Since last year, Climedo has also been making its software available to German health authorities. This allows the authorities to query the symptoms of Covid-19 patients on a daily basis.